Advertisement

Nephrogenic Systemic Fibrosis and Other Scleroderma Mimickers

  • Mark A. Perazella
  • Janet E. Pope
  • Shawn E. Cowper

Abstract

Nephrogenic systemic fibrosis (NSF) is a systemic fibrosing disorder that mimics systemic sclerosis (scle-roderma) and is strongly associated with exposure to gadolinium in the setting of renal insufficiency. In addition to the skin, fibrotic changes can occur in the lungs, diaphragm, muscles, heart, and esophagus. Both clinical and histopathological findings are required to confirm the diagnosis of NSF. No cases of NSF have been described in patients with normal kidney function or mild underlying renal disease. The more severe the kidney dysfunction and the higher the dose of gadolinium, the greater is the risk of NSF. NSF develops subacutely in most cases. It usually becomes apparent first in the lower extremities with symmetrical edema that may involve the upper extremities. The edema may be associated with erythema, blisters, and bullae. Upon resolution of the edema, the indurated skin is nonpitting and “unpinchable.” NSF tends to spare the skin of the face, in contrast to both scleroderma and scleromyxedema. Yellow scleral plaques are described in many cases of NSF. The histopathological features of NSF are consistent with a dermal reaction to injury: fibrocyte-like cells, histiocytes, dermal dendritic cells, scar-like fibrosis, mucin, edema, calcification, and ossification. Scleroderma mimickers such as morphea, scleromyxe-dema, and eosinophilic fasciitis are generally distinguished from scleroderma by their absence of extracutaneous disease, Raynaud's phenomenon, and antinuclear antibodies.

Keywords

Peritoneal Dialysis Acute Kidney Injury Nephrogenic Systemic Fibrosis Normal Kidney Function Localize Scleroderma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Broome DR, Girguis MS, Baron PW, et al Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol. 2007;188:586–92CrossRefGoogle Scholar
  2. Case Records of MGH. Case 6-2008: A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med. 2008;358:827–38Google Scholar
  3. Centers for Disease Control (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents-St. Louis, Missouri, 2002–2006. Morb Mortal Wkly Rep. 2007; 56(7):137–41Google Scholar
  4. Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): Review of 136 patients. J Am Acad Dermatol. 2008;59(3):385–96PubMedCrossRefGoogle Scholar
  5. Collidge TA, Thompson PC, Mark PB, et al Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007;245:168–75PubMedCrossRefGoogle Scholar
  6. Cowper SE. Gadolinium: is it to blame? J Cutan Pathol. 2008; 35(5):520–2PubMedCrossRefGoogle Scholar
  7. Cowper SE, Su L, Robin H, et al Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;23(5):383–93PubMedCrossRefGoogle Scholar
  8. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect iden-tified, motive unclear [letter]. Am J Dermatopathol. 2003;25(4):35CrossRefGoogle Scholar
  9. Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep. 2006a;8(2):151–7CrossRefGoogle Scholar
  10. Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/ nephrogenic systemic fibrosis: Setting the record straight. Semin Arthritis Rheum. 2006b;35(4):208–10CrossRefGoogle Scholar
  11. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol. 2008;66(2):191–9PubMedCrossRefGoogle Scholar
  12. Cowper SE. Nephrogenic fibrosing dermopathy [NFD/NSF Website]. 2001–2008. 2007. http://www.icnfdr.org. Accessed 16 Apr 2008
  13. Dawson P, Punwani S. Nephrogenic systemic fibrosis: non-gadolinium options for the imaging of CKD/ESRD patients. Sem Dial. 2008;51:160–5CrossRefGoogle Scholar
  14. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2:264–7PubMedCrossRefGoogle Scholar
  15. FDA. Information for Healthcare Professionals Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). 2007. http://www.fda.gov/cder/drug/InfoSheets/HCP/gadolinium-con-taining contrast agents_200705.htmGoogle Scholar
  16. Gonwa TA, Jennings L, Mai ML, et al Estimation of glomerular filtra-tion rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl. 2004;10(2):301–9PubMedCrossRefGoogle Scholar
  17. Girardi M. Nephrogenic systemic fibrosis: a dermatologist's perspective. J Am Coll Radiol. 2008;5(1):40–4PubMedCrossRefGoogle Scholar
  18. Grobner T. GBC: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104–8PubMedCrossRefGoogle Scholar
  19. Grobner T, Prischl FC. Patient characteristics and risk factors for neph-rogenic systemic fibrosis following gadolinium exposure. Sem Dial. 2008;21:135–9CrossRefGoogle Scholar
  20. Hawk A, English JC III. Localized and systemic scleroderma. Semin Cutan Med Surg. 2001;20:27–37PubMedCrossRefGoogle Scholar
  21. High WA, Eng M, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:1–2CrossRefGoogle Scholar
  22. Jan F, Segal JM, Dyer J, et al Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr. 2003;143:678–81PubMedCrossRefGoogle Scholar
  23. Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Sem Dial. 2008;21:123–8CrossRefGoogle Scholar
  24. Linfert DR, Schell JO, Fine DM. Treatment of nephrogenic systemic fibro-sis: limited options but hope for the future. Sem Dial. 2008;51:155–9CrossRefGoogle Scholar
  25. Mackay-Wiggan JM, Cohen DJ, Hardy MA, et al Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol. 2003;48:55–60PubMedCrossRefGoogle Scholar
  26. Marckmann P, Skov L, Rossen K, et al Case-control study of gadodi-amide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;22:3174–8PubMedCrossRefGoogle Scholar
  27. Medicines and Healthcare products Regulatory Agency (MHRA). Nephrogenic Systemic Fibrosis (NSF) and gadolinium-containing MRI contrast agents: Public Assessment Report. 2007. http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=CON2030232&RevisionSelectionMethod=LatestReleased Accessed 15 Jul 2008
  28. Othersen JB, Maize JC, Woolson RF, Budisavljevic MN. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant. 2007;22:3179–85PubMedCrossRefGoogle Scholar
  29. Perazella MA. Tissue deposition of gadolinium and development of NSF: a convergence of factors. Semin Dial. 2008;21:150–4PubMedCrossRefGoogle Scholar
  30. Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial. 2007;20:179–85PubMedCrossRefGoogle Scholar
  31. Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc. 1995;70:1068–76PubMedCrossRefGoogle Scholar
  32. Peterson LS, Nelson AM, Su WP, Mason T, O'Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol. 1997;24(1):73–80PubMedGoogle Scholar
  33. Sieber MA, Pietsch H, Walter J, et al A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol. 2008;43(1):65–75PubMedCrossRefGoogle Scholar
  34. Streams BN, Liu V, Liegeois N, Moschella SM. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol. 2003;48:42–7PubMedCrossRefGoogle Scholar
  35. Swaminathan S, High WA, Ranville J, et al Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 2008; 73(12):1413–18PubMedCrossRefGoogle Scholar
  36. Takehara K, Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology (Oxford). 2005;44(3):274–9CrossRefGoogle Scholar
  37. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing der-mopathy with systemic involvement. Arch Dermatol. 2003;139: 903–6PubMedCrossRefGoogle Scholar
  38. Tuffanelli DL. Localized scleroderma. Semin Cutan Med Surg. 1998; 17:27–33PubMedCrossRefGoogle Scholar
  39. Weide B, Schittek B, Klyscz T, et al Morphoea is neither associated with features of Borrelia burgdorferi infection, nor is this agent detectable in lesional skin by polymerase chain reaction. Br J Dermatol. 2000;143(4):780–5PubMedCrossRefGoogle Scholar
  40. Zulian F, Vallongo C, Woo P, et al Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52: 2873–81PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Mark A. Perazella
    • 1
  • Janet E. Pope
    • 2
  • Shawn E. Cowper
    • 3
  1. 1.Division of Nephrology New HavenYale University Medical CenterConnecticutUSA
  2. 2.St. Joseph Health Care LondonLondonCanada
  3. 3.Yale Nephrogenic Systemic Fibrosis RegistryYale University School of Medicine, Yale Dermatopathology ServiceNew HavenUSA

Personalised recommendations